0001716947 false 0001716947 2023-08-28 2023-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 28, 2023 (August 24, 2023)

 

 

Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-38306   82-2755287

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

   92037
(Address of principal executive offices)   (Zip Code)

 

(858) 263-4196

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENSC   The Nasdaq Stock Market LLC

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

(a) The annual meeting of stockholders of Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) was held on August 24, 2023 (the “Annual Meeting”).

 

(b) Three proposals were submitted to the Company’s stockholders.

 

1. The stockholders elected the Company’s two Class II Directors, with terms expiring in 2026:

 

Name  For   Against   Abstentions   Broker Non-Votes 
Bob Gower   222,281.08    20,963    10,655    1,484,119 
Curtis Rosebraugh   223,255.08    11,605    9,039    1,484,119 

 

A quorum being present, the votes properly cast “FOR” each nominee’s election exceeded the votes properly cast “AGAINST” such nominee’s election (with “ABSTENTIONS” and broker non-votes not counted as votes cast either “FOR” or “AGAINST”).

 

2. The stockholders approved the amendment of the Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 31,296 shares to 617,092 shares by the following vote:

 

For  Against   Abstentions   Broker Non-Votes 
202,246.08   50,153    1,500    1,484,119 

 

A quorum being present, votes properly cast “FOR” the proposal constituted a majority of votes cast on the matter, with “ABSTENTIONS” and broker non-votes not counted as votes cast either “FOR” or “AGAINST”.

 

3. The stockholders ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023:

 

For   Against     Abstentions     Broker Non-Votes  
1,631,139.08     16,004       90,875       0  

 

A quorum being present, votes properly cast “FOR” the proposal constituted a majority of votes cast on the matter, with “ABSTENTIONS” and broker non-votes not counted as votes cast either “FOR” or “AGAINST”.

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 28, 2023

 

  Ensysce Biosciences, Inc.
     
  By: /s/ Lynn Kirkpatrick
  Name: Dr. Lynn Kirkpatrick
  Title: President and Chief Executive Officer

 

 3 

 

v3.23.2
Cover
Aug. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 28, 2023
Entity File Number 001-38306
Entity Registrant Name Ensysce Biosciences, Inc.
Entity Central Index Key 0001716947
Entity Tax Identification Number 82-2755287
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7946 Ivanhoe Avenue
Entity Address, Address Line Two Suite 201
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 263-4196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ENSC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Ensysce Biosciences Charts.
Ensysce Biosciences (NASDAQ:ENSC)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Ensysce Biosciences Charts.